&nbsp;

IMPACT_Newsletter_First_Issue

Nov 2019

Document

IMPACT_Newsletter_Second_Edition

Nov 2019

Document

IMPACT_Newsletter_Third_Edition

Nov 2019

Document

IMPACT_Newsletter_Fourth_Edition

Nov 2019

Document

IMPACT_Newsletter_Fifth_Edition

Nov 2019

Regimen

LENV

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Drugs Used:

lenvatinib (Unfunded)

Quick Link(s):

Regimen Monograph

Sep 2020

Regimen

LIPOCYTADAUN(CONS)

Cancer Type:

Hematologic

Intent: Curative, Palliative

Funding:

New Drug Funding Program

Liposomal Daunorubicin and Liposomal Cytarabine (Outpatient) - Previously Untreated Acute Myeloid Leukemia

liposomal DAUNOrubicin / liposomal cytarabine

Drugs Used:

Quick Link(s):

Regimen Monograph

Dec 2023

Regimen

LENV

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

Exceptional Access Program

lenvatinib - For the treatment of unresectable advanced hepatocellular carcinoma according to clinical criteria

Drugs Used:

lenvatinib

Quick Link(s):

Regimen Monograph

Mar 2023

Regimen

IBRU+RITU

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Drugs Used:

iBRUtinib (Unfunded),

riTUXimab (Unfunded)

Quick Link(s):

Regimen Monograph

Aug 2020

Guidelines and Advice

Locoregional Management of In-Transit Metastasis in Melanoma

Status: Current
ID: GL 8-10
Version: N/A

Feb 2020

Regimen

LOMU+BEVA

Cancer Type:

Central Nervous System

Intent: Palliative

Funding:

ODB - General Benefit

lomustine

New Drug Funding Program

Bevacizumab (Biosimilar) - In Combination with Lomustine for Recurrent Glioblastoma

Drugs Used:

lomustine,

bevacizumab

Quick Link(s):

Regimen Monograph

May 2024

Document